ARTICLE | Clinical News
Frova regulatory update
August 15, 2011 7:00 AM UTC
Vernalis disclosed in its 1H11 earnings that Russia approved frovatriptan to treat migraine. Menarini Group (Florence, Italy) has rights to market the selective serotonin (5-HT1B/1D) receptor agonist...